Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

Journal of Immunotherapy

Volumn 19, Issue 1, 1996, Pages 59-68

  MacLean, G D ^a   Reddish, M A ^a   Koganty, R R ^a   Longenecker, B M ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Biomira Inc   (Canada)

Author keywords

Active specific immunotherapy; Cancer vaccine; Sialyl Tn

Indexed keywords

CA 125 ANTIGEN; CANCER VACCINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; LACTATE DEHYDROGENASE; PHOSPHORYL LIPID A; THERATOPE; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OVARY ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0029873154     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199601000-00007     Document Type: Article

References (27)

1. Miller K, Abeles G, Oratz R, et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995;75: 495-502.
2. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49:7045-50.
3. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981;66:249.
4. Konstadoulakis MM, Syrigos KN, Albanopoulos C, Mayers G, Golematis B. The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies. J Clin Immunol 1994;49:310-13.
5. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994;12:1497-1515.
6. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343:1177-83.
7. Yamasha Y, Chung YS, Horie R, Kannagi R, Sowa M, Alterations in gastric mucin with malignant transformation: novel pathway for mucin synthesis. J Natl Cancer Inst 1995; 87:441-6.
8. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S-I, Kim YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66:1960-6.
9. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992;10:95-101.
10. Werther JL, Rivera-MacMurray S. Tatematsu M. Ito N, Bruckner H, Itzkowitz SH. Sialosyl-Tn: a novel mucin antigen associated with poor prognosis in gastric cancer patients. Proc Am Assoc Cancer Res 1991;32:241.
11. Longenecker BM, Reddish M, Miles D, MacLean GD. Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res 1993;2:151-62.
12. Longenecker BM, Reddish M, Koganty R, MacLean GD. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis. In: Ceriani RL, ed. Antigen and antibody molecular engineering in breast cancer diagnosis and treatment. New York: Plenum Press, 1994:105-24.
13. Longenecker BM, MacLean GD. Prospects for mucin epitopes in cancer vaccines. Immunologist 1993;1:89-93.
14. MacLean GD, Reddish MA, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993;36:215-22.
15. Mellstedt H, Frödin J-E, Masucci G, et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1991;18:462-77.
16. Fung PYS, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-Ha). Cancer Res 1991;51:1170-6.
17. Fagerberg J, Hjelm A-L, Ragnhammar P, Frödin J-E, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of antiidiotype-reactive T lymphocytes. Cancer Res 1995;55: 1824-7.
18. Longenecker BM, Reddish M, Koganty R, MacLean GD, Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus DETOX adjuvant. Ann NY Acad Sci 1993;690: 276-91.
19. O'Boyle KP, Zamore R, Adluri S, et al. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res 1992;52:5663-7.
20. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S-I. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2 → 6α-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988;48:2214-20.
21. Pigman W, Gottschalk A. Submaxillary gland glycoproteins. In: Gottschalk A, ed. Glycoproteins. Vol 5. New York: Elsevier, 1966:434-45.
22. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM. Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC-1 gene. J Tumor Marker Oncol 1992;7:19-27.
23. Jensen JL, MacLean GD, Suresh MR, et al. Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management. Int J Biol Markers 1990;6:1-6.
24. Frenette PS, Thirlwell MP, Trudeau M, Thomson DMP, Joseph L, Shuster JS. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumor Biol 1994;15:247-54.
25. Abacus Concepts. Survival tools for StatView. Berkeley, CA: Abacus Concepts, Inc., 1994.
26. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
27. Berd D, Maguire HC, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984;44:5439-43.